Search

Your search keyword '"Ginevra Fiori"' showing total 66 results

Search Constraints

Start Over You searched for: Author "Ginevra Fiori" Remove constraint Author: "Ginevra Fiori"
66 results on '"Ginevra Fiori"'

Search Results

2. Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis

3. Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience

4. The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases

6. The positive side of the coin: Sars-Cov-2 pandemic has taught us how much Telemedicine is useful as standard of care procedure in real life

7. Persistence of remission after lengthening of golimumab in inflammatory joint diseases

8. The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases

9. Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases

10. AB0256 BARICITINIB (BARI) VERSUS BIOLOGICS IMPACT ON STEROID TAPERING IN RHEUMATOID ARTHRITIS (RA)

11. AB0361 EFFICACY AND SAFETY OF BARICITINIB (BARI) IN RHEUMATOID ARTHRITIS(RA): CLINICAL AND ULTRASOUND EVALUATION IN REAL LIFE

12. Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases

13. AB0369 SAFETY, EFFICACY AND RETENTION RATE OF BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (BDMARDS) IN ASSOCIATION WITH DENOSUMAB: COMPARISON OF COMBINATION AND MONO-THERAPY REGIMENS

14. POS0618 PERSISTENCE OF REMISSION AFTER TAPERING OF GOLIMUMAB IN INFLAMMATORY JOINT DISEASE (IJD)

15. POS1495-HPR THE EXPERIENCE OF A RHEUMATOLOGY UNIT DURING THE COVID19 LOCKDOWN: TELEMEDICINE ALLOWS A SAFE FOLLOW UP OF PATIENTS WITH RHEUMATIC DISEASES

16. Assessment, Definition, and Classification of Lower Limb Ulcers in Systemic Sclerosis: A Challenge for the Rheumatologist

17. AB0239 EFFECTS OF DYSMETABOLISMS AND COMORBIDITIES ON THE EFFICACY, SAFETY AND RETENTION RATE OF BIOLOGICAL DMARDS (bDMARD) IN INFLAMMATORY JOINT DISEASES

18. THU0360 EFFICACY OF A SELF-TREATMENT PROTOCOL FOR FACE AND TEMPOROMANDIBULAR JOINTS REHABILITATION IN SYSTEMIC SCLEROSIS (SSC)

19. The safety of iloprost in systemic sclerosis in a real-life experience

20. The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders

21. The challenge of pet therapy in systemic sclerosis: evidence for an impact on pain, anxiety, neuroticism and social interaction

22. Disease Activity Improvement in Rheumatoid Arthritis Treated with Tumor Necrosis Factor-α Inhibitors Correlates with Increased Soluble Fas Levels

23. Long-term treatment of scleroderma-related digital ulcers with iloprost: a cohort study

24. Lidocaine controls pain and allows safe wound bed preparation and debridement of digital ulcers in systemic sclerosis: a retrospective study

25. Premedication prevents infusion reactions and improves retention rate during infliximab treatment

26. Bone marrow-derived mesenchymal stem cells from early diffuse systemic sclerosis exhibit a paracrine machinery and stimulate angiogenesis in vitro

27. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases

28. Autologous stem cell transplantation improves microcirculation in systemic sclerosis

29. Therapeutic Challenges for Systemic Sclerosis: Facts and Future Targets

30. Exercise Doppler Echocardiography Identifies Preclinic Asymptomatic Pulmonary Hypertension in Systemic Sclerosis

31. Flow-Mediated Vasodilation and Carotid Intima-Media Thickness in Systemic Sclerosis

32. Angiotensin-converting enzyme I/D polymorphism and macrovascular disease in systemic sclerosis

33. Calcinosis in systemic sclerosis: subsets, distribution and complications

34. Melatonin is a safe and effective treatment for chronic pulmonary and extrapulmonary sarcoidosis

35. Pulmonary arterial hypertension in systemic sclerosis: diagnostic pathway and therapeutic approach

36. The pathogenesis of inflammatory muscle diseases

37. Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study

38. Digital ulcers as a sentinel sign for early internal organ involvement in very early systemic sclerosis

39. Serial QuantiFERON TB-Gold in-tube testing during LTBI therapy in candidates for TNFi treatment

40. AB0623 Treatment of Scleroderma-Related Digital Ulcers with Iloprost: A Cohort Study

41. THU0641-HPR The Challenge of Pet Therapy in Rheumatology: Evidence for The Improvement of Patients Compliance in Systemic Sclerosis

42. SAT0582 Incidence of Malignancies in Patients with Inflammatory Rheumatic Diseases and Biological Drugs: Experience from One Center in Italy

43. AB0637 Iloprost (ILO) in Systemic Sclerosis (SSC): The Safety Experience of Two Italian Centres

44. The treatment of skin ulcers in patients with systemic sclerosis

45. Autologous mesenchymal stem cells foster revascularization of ischemic limbs in systemic sclerosis: a case report

46. Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions

47. Transitional Connective Tissue Diseases: Description of Four Cases

48. Reduced circulating levels of angiotensin-(1--7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control

49. FRI0465 Animal (PET)-Assisted Therapy Helps in Reducing Pain and Promotes Social-Affective Regulation in Systemic Sclerosis (SSC)

50. The pathogenesis of inflammatory muscle diseases: on the cutting edge among the environment, the genetic background, the immune response and the dysregulation of apoptosis

Catalog

Books, media, physical & digital resources